ALS drug Relyvrio withdrawn from market after failed clinical trial

Amylyx Pharmaceuticals has initiated the voluntary withdrawal of its ALS drug, Relyvrio, due to its lack of proven efficacy in a large clinical trial. The company stated that Relyvrio will no longer be available for new patients, but current patients can transition to a free drug program if they wish to continue the treatment. The Phase 3 clinical trial demonstrated that Relyvrio did not outperform a placebo in improving participants’ ALS functional scale, patient-reported quality of life, overall survival, and respiratory function. Amylyx will reduce its workforce and prioritize funding for ongoing studies of experimental drugs for other neurodegenerative disorders.